BridgeMD
New treatment option for Cancer-associated Thrombosis
Official title STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
ClinicalTrials.gov ID: NCT05255003
What this study is testing
What is Enoxaparin?
Enoxaparin is an investigational medicine, given as an once-daily injection under the skin, being studied as a potential treatment for cancer-associated thrombosis.
Also referred to as Lovenox.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients (age ≥ 18) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive/relapsed);
- Objectively confirmed VTE within last 14 days for which therapeutic anticoagulation is planned;
- Thrombocytopenia with a platelet count \< 50,000/uL from cancer therapy or malignancy itself;
- Able to provide written informed consent
You likely can't join if
- Receipt of anticoagulant for index VTE with platelet count \ 72 hours;
- Superficial vein thrombosis only;
- Life expectancy \< 1 month (as judged by the treating physicians);
- Creatinine clearance \< 30 ml/min;
- Contraindication to LMWH such as a history of heparin induced thrombocytopenia;
- Thrombocytopenia from other causes, such as thrombotic microangiopathy, immune thrombocytopenia, disseminated intravascular coagulation;
See the full eligibility criteria
- Adult patients (age ≥ 18) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive/relapsed);
- Objectively confirmed VTE within last 14 days for which therapeutic anticoagulation is planned;
- Thrombocytopenia with a platelet count \< 50,000/uL from cancer therapy or malignancy itself;
- Able to provide written informed consent
- Receipt of anticoagulant for index VTE with platelet count \ 72 hours;
- Superficial vein thrombosis only;
- Life expectancy \< 1 month (as judged by the treating physicians);
- Creatinine clearance \< 30 ml/min;
- Contraindication to LMWH such as a history of heparin induced thrombocytopenia;
- Thrombocytopenia from other causes, such as thrombotic microangiopathy, immune thrombocytopenia, disseminated intravascular coagulation;
- Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies;
- Refusal of blood products;
- Anticoagulation at any dose is deemed unsafe (i.e. active bleeding or bleeding disorders)
The study team makes the final eligibility decision.
Where it's taking place
- Edmonton, Alberta, Canada
- Ottawa, Ontario, Canada
- Saint Catharines, Ontario, Canada
- Windsor, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Edmonton, Alberta, Canada; Ottawa, Ontario, Canada; Saint Catharines, Ontario, Canada; Windsor, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.